Cardiome Pharma (CRME) Jumps on U.K. Nod

Cardiome Pharma Corp. CRME shares galloped 3.8% to $9.61,on word that the Secretary of State for the U.K. Department of Health has approved pricing for BRINAVESS® (vernakalant hydrochloride). The approved amount represents a maximum price per vial of BRINAVESS® in the United Kingdom. It is consistent with pricing in other territories and Cardiome's economic forecasts. Share volume was 14,700